Immutep announces site expansion for INSIGHT-003 Phase I trial

Immutep announces that the INSIGHT-003 trial has been expanded to four sites across Germany including the University Clinic of Ruhr Universitat Bochum and the Lung Clinic Cologne-Merheim. This site expansion will support faster enrolment in this cost-efficient, investigator-initiated study evaluating eftilagimod alpha in combination with the anti-PD-1 therapy KEYTRUDA and doublet chemotherapy for first line treatment of non-squamous non-small cell lung cancer. The strength of the early clinical data in this first-in-man triple combination study led to its increase to 50 patients. The extension opened in mid-2023 and 29 patients have been enrolled to date. With the addition of the new sites, the trial is expected to complete recruitment in 1H CY2024.